Hundreds of studies and results were presented at the 61st American Society of Hematology (ASH) Annual Meeting.

Astex Pharmaceuticals and Otsuka Pharmaceutical announced that the companies’ ASCERTAIN Phase III clinical trial of cedazuridine and decitabine (ASTX727) compared to decitabine IV alone hit the study’s primary endpoints.

Celgene and developmental partner Acceleron Pharma are eying a potential U.S. FDA approval of a blood-disease treatment.

There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.